Search the webpage

Created by Jenni J. Hakkarainen on   November 22, 2018   in category: News

Experimentica Ltd. opens a new R&D site in Vilnius, Lithuania

Experimentica Ltd. announced the opening of a new Research & Development site in Vilnius, Lithuania, which will strengthen the company’s global position as a leader in the ophthalmic contract research organization market. The new corporate entity, Experimentica UAB, is fully owned and operated by the parent company Experimentica Ltd., headquartered in Kuopio, Finland.

“Our new R&D site will significantly increase our capacity for high-resolutionin vivoimaging and ocular tolerability and toxicology studies and strengthen Experimentica Ltd.’s position in this market segment”, said Dr. Giedrius Kalesnykas, Founder and CEO of the company. “We are very grateful for the support by the European Union and excited to help our clients accelerate their ophthalmic drug discovery efforts.”

The investment totaling €1.6 million was supported, in part, by a competitive award “Smart FDI” (project no. 01.2.1-LVPA-T-848-01-0005) under the Promotion of Scientific Research, Experimental Development and Innovations Priority of the Operational Programme of the European Union Structural Funds for 2014-2020.

The funded research project “Development and validation of preclinical models for research of advanced therapeutics” is dedicated to developing and validating novel preclinical ophthalmic disease-specific models, enabled by novel research on the pathophysiological mechanisms and the use of non-invasive imaging modalities. The availability of these novel preclinical models will help bridge the gap between preclinical discovery of novel exosome-based advanced therapeutics for ocular diseases and their translation to the clinic.

“The continued investment into state-of-the-art imaging devices supported by this programmatic EU funding will be crucial in sustaining Experimentica’s role as industry leader for the functional analysis of the visual system and allow us to be at the forefront of model development for the preclinical testing of ophthalmic drug candidates for our clients”, said Dr. Simon Kaja, Chief Scientific Officer of Experimentica.

Contact for media enquiries:

Jenni J. Hakkarainen, Ph.D.
Chief Operating Officer
Phone: +358 (40) 930-7087


Experimentica Ltd. presents strategic roadmap and announces €3,05M investment in artificial intelligence for preclinical efficacy and safety testing of ophthalmic drug candidates

Experimentica Ltd. revealed its strategic plan that outlines a roadmap for the development of artificial intelligence (AI)-based algorithms aimed at ... Read More

Experimentica Ltd. participates in ORBITAL, an EU Horizon 2020 Marie Sklodowska-Curie Innovative Training Network award

Experimentica Ltd. is pleased to announce its participation as beneficiary in EU Horizon 2020 Marie Sklodowska-Curie Innovative Training Network award ... Read More

A retinal organotypic model for ex vivo neuroprotection studies

A recently published study by Experimentica Ltd. and its collaborators from the University of Tampere, Finland, shows that when the ... Read More

Subscribe to Our Newsletter!

We promise that no sales pitches will be attached to newsletter. And don't worry, we hate spammers too!